Episode Details

Becton Dickinson (BDX) Q3 FY2026 — Q3 FY2026 (quarter ended June 30, 2026): revenue $4,983M vs $4,726M, +5.4% reported and +4.4% currency-neutral, against a $4,887M bar - a 2.0% beat. GAAP diluted EPS from continuing operations $1.64 vs $1.57 (+4.5%); adjusted diluted EPS $3.23 vs $3.08 (+4.9%), against a $3.14 bar - a nine-cent BEAT. Total GAAP EPS including discontinued operations $1.37. FY2026 adjusted EPS guidance raised at the midpoint to $12.62-$12.72 from $12.52-$12.72. The 8-K was accepted at 6:31 a.m. ET Thursday Aug 6, so Thursday WAS the reaction: +3.76% to $177.07 from $170.66. Friday Aug 7 closed $176.86, -0.12% - the move held. A wall of coverage called BD's fiscal Q3 a miss, comparing GAAP EPS of $1.64 against a stale pre-separation estimate above $2. It was not a miss - FMP's own tracked actual is the adjusted $3.23 against a $3.14 bar. But the usual explanation is wrong too: 83% of the $1.59 GAAP-to-adjusted gap is purchase-accounting amortisation ($1.32/share, and it was $1.31 a year ago), not separation noise. Only $0.12 is separation cost. And the beat is not a beat either: GAAP net income from continuing operations was $451M in both years, to the dollar, and adjusted net income rose $4.2M. Our fair value is $176 against the $176.86 close. THE CALL: HOLD (3/5, A FAIRLY PRICED BUSINESS WITH NO MARGIN OF SAFETY, WHERE THE EARNINGS DOLLARS HAVE NOT ACTUALLY GROWN) — base-case value ~$176.0 vs ~$176.86 today. KEY METRICS: - CALL: HOLD 3/5, fair value $176 vs the $176.86 Aug 7 close (-0.5%). Bull $249, bear $111. Street: Hold, 34 analysts, avg target $185.63. - Revenue $4,983M +5.4%; adjusted EPS $3.23 vs a $3.14 bar. But GAAP net income from continuing ops was $451M in BOTH years - flat to the dollar. - 90% of the 15c adjusted EPS gain is the buyback: shares -4.2%. On last year's share count the quarter earned $3.09 - below the $3.14 bar. What to watch: UP: adjusted operating margin finally guided higher as Excellence Unleashed removes stranded costs (GAAP operating margin fell 234bp to 13.3% this quarter); Medication Delivery (+1.6% FXN) and Medication Management (+2.3% FXN) inflecting - together almost half the company; owner earnings reaching $2.85B, which returns $249 in our model; further debt paydown lowering the discount rate. DOWN: the working-capital swing reversing (it was 107% of the nine-month operating cash flow increase); tariffs, which BD bases guidance on as of Aug 5 with certain refunds unresolved; the buyback ending when the $3.86B Waters distribution is spent, leaving EPS to grow the hard way. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.